|
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance Clinical research trials and Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance. Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance  Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance
For Condition: Neoplasm
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment). Many patients with cancer improve initially with chemotherapy, but then have a disease relapse, after which their tumor no longer responds to treatment. Other patients' tumors are drug-resistant from the start. The study will look for "resistance factors"-substances in blood and tissues that render tumors resistant to chemotherapy. The findings may provide information needed to develop methods of combating drug resistance. Patients with cancer who are 18 years or older may be eligible for this study. Participants will have 40 milliliters (3 tablespoons) of blood drawn at the beginning of the study; additional samples will be obtained periodically during the course of treatment. A small sample of tumor or normal tissue will be taken from patients who undergo surgery or tumor biopsy (removal of a small piece of tumor) for medical reasons or as part of a research treatment protocol. Patients who do not require surgery or biopsy may be asked permission to obtain a tumor sample. Depending on the location of the tumor, this may be done by: 1) withdrawing bone marrow through a small needle; 2) removing fluid from the chest or abdomen; 3) removing a small tumor sample through a needle; or 4) removing the sample with a small incision into or around the tumor. These procedures will be done only if they are of low risk to the patient.
Details: Patients with a prior diagnosis of malignancy, with advanced or refractory cancer will be evaluated in the Medical Oncology Clinic, NCI. Blood samples may be collected at the initial visit, and at followup visits. Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, or by excisional biopsy, providing the tumor is accessible with a minimal risk to the patient. Specific risks will be described in a separate consent to be obtained at the time of the biopsy. Tumor samples and blood samples will be processed and stored in the Experimental and Molecular Therapeutics Sections, NCI, for use in research efforts of the Section.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients 18 years of age and older are eligible. Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this protocol. Patients with malignancy are eligible. Patients requiring a surgical procedure for any medical indication can be included on study. Patients requiring biopsy or any procedure for any medical indication can be included on study. Patients not requiring biopsy for a medical indication can be included solely for the purpose of obtaining research samples, including blood, pleural fluid, or peritoneal fluid, or biopsy samples, providing the biopsy or aspiration procedure is of minimal risk, i.e., fine needle aspirate, bone marrow aspirate, or excisional biopsy. EXCLUSION CRITERIA: Pregnant patients will not be eligible due to potential risks to the fetus associated with radiologic procedures required for biopsy. HIV patients will not be eligible since the immunodeficiency may put them at greater risk from complications due to the procedures involved in obtaining the biopsies. Children will not be eligible because of potential risks from complications due to procedures involved in obtaining the biopsies.
Total Enrollment: 100
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 000078; 00-C-0078
Study Start Date: February 11, 2000
Record last reviewed: February 1, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00026663
Other Neoplasm Studies:
1. Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance
2. Phase 1 Study of Imatinab (STI571) in Patients with Advanced Cancer and Kidney Dysfunction
3. A Phase I Trial of Continuous Infusion UCN-01 in Patients with Refractory Neoplasms
4. Cellular Immunotherapy with Autologous T Lymphocytes Stimulated with the Patient's Tumor-Specific Mutated Ras Peptides
5. A Phase I Study of Weekly Gemcitabine Given in Combination with Infusional Fluorouracil and Oral and Intravenous Calcium Leucovorin in Adult Cancer Patients
Related Studies:
Other Neoplasm Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer to Study Drug Resistance
|
|
|
|
|
|
|
|
